| scholarly article | Q13442814 |
| P50 | author | Matthew Lawrenz | Q33295608 |
| Lalit Batra | Q91610229 | ||
| P2093 | author name string | Esma S Yolcu | |
| Haval Shirwan | |||
| Amanda R Pulsifer | |||
| William Bowen | |||
| P2860 | cites work | The Role of Early-Phase Transmission in the Spread of Yersinia pestis | Q26786038 |
| Plague Vaccine Development: Current Research and Future Trends | Q28066875 | ||
| Multiple antimicrobial resistance in plague: an emerging public health risk | Q33279527 | ||
| A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | Q33586493 | ||
| Human immune response to a plague vaccine comprising recombinant F1 and V antigens | Q33788286 | ||
| 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines | Q33857971 | ||
| Milestones in progression of primary pneumonic plague in cynomolgus macaques | Q33963187 | ||
| Yersinia pestis (plague) vaccines | Q34324211 | ||
| TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. | Q34380204 | ||
| Development of bioluminescent bioreporters for in vitro and in vivo tracking of Yersinia pestis. | Q34447928 | ||
| IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection | Q34786724 | ||
| Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge | Q34819434 | ||
| Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague | Q35091255 | ||
| Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges | Q35418294 | ||
| Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation. | Q35779013 | ||
| Development of in vitro correlate assays of immunity to infection with Yersinia pestis. | Q35783560 | ||
| Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent | Q35987596 | ||
| Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy | Q36375551 | ||
| SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines | Q36487245 | ||
| Current challenges in the development of vaccines for pneumonic plague | Q36628038 | ||
| Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial | Q37264991 | ||
| The role of TNF superfamily members in T-cell function and diseases | Q37332068 | ||
| Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors | Q37370587 | ||
| Live-attenuated Yersinia pestis vaccines | Q38113270 | ||
| Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague | Q38671761 | ||
| Pneumonic Plague: The Darker Side of Yersinia pestis | Q38677618 | ||
| Cell-mediated protection against pulmonary Yersinia pestis infection | Q39393406 | ||
| Plague Immunization. I. Past and Present Trends | Q39940120 | ||
| MAP of F1 and V antigens from Yersinia pestis astride innate and adaptive immune response | Q41374736 | ||
| Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant | Q41384167 | ||
| Preclinical safety assessment of a recombinant plague vaccine (rF1V). | Q41394769 | ||
| Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model | Q41400297 | ||
| Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model | Q41406576 | ||
| Evaluation of CD4+/CD8+ T-cell expression and IFN-γ, perforin secretion for B-T constructs of F1 and V antigens of Yersinia pestis. | Q41422910 | ||
| Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. | Q41428963 | ||
| Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis | Q41434326 | ||
| CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. | Q41438984 | ||
| Antibodies and cytokines independently protect against pneumonic plague. | Q41441607 | ||
| Development of a recombinant vaccine against aerosolized plague | Q41450195 | ||
| Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection | Q41451306 | ||
| Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates | Q41451391 | ||
| Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection | Q41453869 | ||
| Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen ofYersinia pestisusing novel delivery vehicles | Q41465431 | ||
| A single dose sub-unit vaccine protects against pneumonic plague | Q41478002 | ||
| An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model | Q41483141 | ||
| Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine | Q41485426 | ||
| A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague | Q41488013 | ||
| A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model | Q41493178 | ||
| Membrane-bound Fas ligand only is essential for Fas-induced apoptosis | Q42093656 | ||
| SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines | Q42186082 | ||
| Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo | Q48020828 | ||
| Plague | Q56706594 | ||
| A brief history of biological weapons programmes and the use of animal pathogens as biological warfare agents | Q64360772 | ||
| Plague | Q75331478 | ||
| Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling | Q79912637 | ||
| P433 | issue | 38 | |
| P921 | main subject | Yersinia pestis | Q153875 |
| P304 | page(s) | 5708-5716 | |
| P577 | publication date | 2019-08-12 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague | |
| P478 | volume | 37 |
Search more.